allostim
Vaccineexperimental
Clinical trial activity
18 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
15
Phase 3
2
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00861107)
Timeline
Indications
Studied for
- Back Pain · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2/Phase 3
- COVID-19 · Phase 1/Phase 2
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 1/Phase 2
- Influenza, Human · Phase 1/Phase 2
- Intervertebral Disc Degeneration · Phase 1/Phase 2
- Leukemia · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pneumonia · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Respiratory Distress Syndrome · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Virus Diseases · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allostim
- allostim-7
- allostim-8
- allostim-9
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06557278 | Phase 2 | Nov 30, 2024 | Mirror Pharms |
| NCT06053242 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Creative Medical Technology Holdings Inc |
| NCT05626712 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2023 | Creative Medical Technology Holdings Inc, University of Miami |
| NCT05033522 | Phase 2/Phase 3 (Phase 3) | Feb 28, 2022 | Immunovative Therapies, Mirror Pharms |
| NCT04444622 | Phase 2 | Jan 6, 2021 | Immunovative Therapies, Mirror Pharms |
| NCT04441047 | Phase 1/Phase 2 (Phase 2) | Jan 6, 2021 | Immunovative Therapies, Mirror Pharms |
| NCT01741038 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2017 | Immunovative Therapies, National Cancer Institute of Thailand |
| NCT02380443 | Phase 2 | Sep 1, 2016 | Immunovative Therapies, University of Texas at Houston |
| NCT02409524 | Phase 2 | Jul 1, 2016 | Immunovative Therapies, National Cancer Institute (NCI) |
| NCT02018419 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Immunovative Clinical Research, Immunovative Therapies |
| NCT01998542 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Immunovative Therapies |
| NCT01995227 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Hebrew University, Immunovative Therapies |
| NCT01923233 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2013 | Immunovative Therapies |
| NCT00861965 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Immunovative Therapies |
| NCT00558675 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2009 | Hebrew University, Immunovative Therapies |
| NCT01065441 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2009 | Hebrew University, Immunovative Therapies |
| NCT00861107 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2009 | Immunovative Therapies |
| NCT07137559 | N/A | — | Creative Medical Technology Holdings Inc |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunovative Therapies | For profit | 14 | 14 | 2 | 2009 |
| Mirror Pharms | For profit | 4 | 1 | 2 | 2021 |
| Creative Medical Technology Holdings Inc | For profit | 3 | 3 | 2 | 2023 |
| Hebrew University | Academic/Hospital | 3 | 0 | 1 | 2009 |
| Immunovative Clinical Research | For profit | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Cancer Institute of Thailand | Government | 1 | 0 | 1 | 2017 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2016 |
9 organizations
Page 1 / 1